Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Phytomedics Provides Phase 2b Rheumatoid Arthritis Trial Results
Phytomedics has published the results of a six month, phase 2b clinical trial with an extract of Tripterygium wilfordii Hook F (TwHF) in August 18, 2009 issue of
Phytomedics has published the results of a six month, phase 2b clinical trial with an extract of Tripterygium wilfordii Hook F (TwHF) in August 18, 2009 issue of
Entest BioMedical, a subsidiary of Bio-Matrix Scientific (BMSN), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary
Bayer Schering has submitted an application for registration of a new formulation of Levitra (vardenafil HCI) in the EU. The company claims that in contrast to other drugs
FDA has licensed the CSL Biotherapies’ (CSL) newest vaccine filling and packaging facility, located in Kankakee, Illinois. The facility, part of an investment to expand CSL’s US influenza
Cerus has reported that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with Cerus’ Intercept Blood System. The approval extends permitted storage time
Mylan has reported that the company and its subsidiary, Mylan Pharmaceuticals has filed a civil lawsuit in the Circuit Court of Monongalia County, WVa, against the Pittsburgh Post-Gazette,
Peplin has completed the enrolment in second phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), on non-head treatment
Novartis has published data for Femara (letrozole) following surgery, as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive), in the
Advaxis has formed a collaboration with investigators at City of Hope. It is for the development of a vaccine to treat certain forms of leukemia and lymphoma, based
Nycomed has reported sustained momentum in the second quarter of 2009, with total net turnover increasing by 0.5% to E786.9m for the first half of 2008. Adjusted EBITDA